We use advanced full in-house isolation and characterization techniques to expand our unique strain collection.
Isolation using flow cytometry under anaerobic conditions, an innovative method recently published, is the highly innovative tool we co-develop with Bioaster.
Characterization goes through a full proprietary workflow of genetic, morphological, and biochemical assays using a mix wet-lab and bioinformatical methods. This step is in line with LBP regulatory expectations and allows a primary evaluation of the strain potential for therapeutic application.

Discover our related scientific publications:

• Entering First-in-Human Clinical Study With a Single-Strain Live Biotherapeutic Product: Input and Feedback Gained From the EMA and the FDA (Paquet et at. 2021)
• Species-targeted sorting and cultivation of commensal bacteria from the gut microbiome using flow cytometry under anaerobic conditions (Bellais et al. 2022)

YSOPIA is the first biotech to harness the therapeutic potential of Christensenella.
We have built the largest standardized collection of Christensenella strains worldwide, as well as a recognized know-how to advance specific strains of interest towards clinical development.

• Identifying a Novel Bile Salt Hydrolase from the Keystone Gut Bacterium Christensenella minuta (Dejean et al. 2021)

Preselected strains undergo an efficient screening process oriented toward therapeutical efficacy. A combination of in silico, in vitro and in vivo evaluation allows to select the best drug candidate to be pushed further into preclinical and clinical development.

Discover our related scientific publications:

• A New Strain of Christensenella minuta as a Potential Biotherapy for Obesity and Associated Metabolic Diseases (Mazier et al. 2021)
• The Keystone commensal bacterium Christensenella minuta DSM 22607 displays anti-inflammatory properties both in vitro and in vivo (Kropp et al. 2021)

Our added value is to rapidly run our drug candidate into patients while guaranteeing safety, efficacy and ensuring the rapid passage of our innovative biotherapies onto the market.

We gather unique expertise in single-strain Live Biotherapeutic Products development.
Thanks to our systematic and continuous exchanges with both US and European regulatory agencies, we have built a successful regulatory package for LBP development:

• Microbiome-oriented internal preclinical protocols and analysis
• Full controlled proprietary cGMP manufacturing process adaptable to any anaerobe
• Development of clinical protocols adapted to LBP supported by world- renowned KOLs & CABs
• Microbiome-oriented clinical biomarker analysis based on cutting-edge OMICs technologies

Discover our related scientific publications:

• Entering First-in-Human Clinical Study With a Single-Strain Live Biotherapeutic Product: Input and Feedback Gained From the EMA and the FDA (Paquet et at. 2021)